Clinical Trials Logo

Hyperlipidemia Combined clinical trials

View clinical trials related to Hyperlipidemia Combined.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT00349284 Completed - Clinical trials for Hyperlipidemia Combined

A Controlled-Study of Fenofibrate 145 mg and Ezetimibe 10 mg in Type IIb Dyslipidemic Patients With Features of the Metabolic Syndrome

Start date: January 2005
Phase: Phase 3
Study type: Interventional

Type IIb dyslipidemia is characterized by elevated triglycerides (TG ³ 150 mg/dL), and elevated LDL-C levels (³160 mg/dL). When in addition, HDL-C is low, the presence of the lipid triad, elevated TG and LDL-C and low levels of HDL-C, seems to confer additional CHD risk in this type of patient, compared to elevated LDL-C alone.Coadministration of fenofibrate and ezetimibe could provide a complementary efficacy therapy and improve the atherogenic profile of this patient population.